With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

Conshohocken’s Madrigal inks a $4B-plus global deal to expand its MASH drug pipeline beyond blockbuster Rezdiffra.

A CHEMICAL-FREE alternative to surgical mulesing of sheep is closer with University of Queensland development of technology that improves the efficacy of treatments to hinder and kill blowfly ...

Irish biotech Aerska raises €32M to deliver RNA medicines to the brain, targeting Alzheimer’s and Parkinson’s at their ...

According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from ...

Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported fourth-quarter net income of $111.5 million, after reporting a loss ...

If you are wondering whether Alnylam Pharmaceuticals at around US$308.48 is still priced sensibly after its run in the biotech space, you are not alone. The stock has seen a 6.9% decline over the last ...

This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial. The results of a clinical trial, called VIBRANT-HD, investigating an oral ...

Alnylam Pharmaceuticals achieved profitability for the first time in its history in 2025. | Alnylam achieved profitability for the first time in its history in 2025. But disappointing sales ...

The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, ...

Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today ...